Search results: Sage Journals

Restricted accessResearch articleFirst published April, 2005

Pattern of neuropsychological impairment in the early phase of relapsing-remitting multiple sclerosis

T Olivares, A Nieto, M P Sánchez [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published May, 2021

Theory of Mind Deficits and Their Influence on Functional Impairment in Remitted Phase of Bipolar Disorder

Pradeep Palaniappan, Krishnapriya Easwaran

Indian Journal of Psychological Medicine

Restricted accessResearch articleFirst published June, 2011

Probiotic helminth administration in relapsing–remitting multiple sclerosis: a phase 1 study

JO Fleming, A Isaak, JE Lee [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published March, 2012

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study

Ludwig Kappos, Ralf Gold, David H Miller [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published June, 1995

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients

LD Jacobs, DL Cookfair, RA Rudick [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published December, 2023

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Barry A Singer, Douglas L Arnold, Jelena Drulovic [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published November, 2020

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Robert T Naismith, Jerry S Wolinsky, Annette Wundes [...]

Multiple Sclerosis Journal

Free accessResearch articleFirst published March, 2015

A pilot,longitudinal,24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing–remitting multiple sclerosis

Robert Zivadinov, Michael Dwyer, Silva Markovic-Plese [...]

Therapeutic Advances in Neurological Disorders

Free accessResearch articleFirst published January, 2017

Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE

Scott D. Newsome, Bernd C. Kieseier, Shifang Liu [...]

Therapeutic Advances in Neurological Disorders

Restricted accessResearch articleFirst published January, 1997

Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials

L Truyen, F Barkhof, M Tas [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published April, 2005

Pattern of neuropsychological impairment in the early phase of relapsing-remitting multiple sclerosis

T Olivares, A Nieto, M P Sánchez [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published May, 2021

Theory of Mind Deficits and Their Influence on Functional Impairment in Remitted Phase of Bipolar Disorder

Pradeep Palaniappan, Krishnapriya Easwaran

Indian Journal of Psychological Medicine

Restricted accessResearch articleFirst published June, 2011

Probiotic helminth administration in relapsing–remitting multiple sclerosis: a phase 1 study

JO Fleming, A Isaak, JE Lee [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published March, 2012

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study

Ludwig Kappos, Ralf Gold, David H Miller [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published June, 1995

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients

LD Jacobs, DL Cookfair, RA Rudick [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published December, 2023

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Barry A Singer, Douglas L Arnold, Jelena Drulovic [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published November, 2020

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Robert T Naismith, Jerry S Wolinsky, Annette Wundes [...]

Multiple Sclerosis Journal

Free accessResearch articleFirst published March, 2015

A pilot,longitudinal,24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing–remitting multiple sclerosis

Robert Zivadinov, Michael Dwyer, Silva Markovic-Plese [...]

Therapeutic Advances in Neurological Disorders

Free accessResearch articleFirst published January, 2017

Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE

Scott D. Newsome, Bernd C. Kieseier, Shifang Liu [...]

Therapeutic Advances in Neurological Disorders

Restricted accessResearch articleFirst published January, 1997

Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials

L Truyen, F Barkhof, M Tas [...]

Multiple Sclerosis Journal